NeOnc Technologies Sets Phase 2 Dose for NEO-212 Brain Cancer Therapy | NewsOut

Biotech and healthcare investors: NeOnc Technologies Holdings announced new clinical progress in its Phase 1/2 trial of NEO-212, an oral bioconjugated therapy being developed for central nervous system cancers. Reporting from the New York Stock Exchange, Jane King explains the company reached the maximum tolerated dose during the Phase 1 dose-escalation stage, establishing 610 mg as the recommended Phase 2 dose. Early signals of disease control were observed in heavily pretreated patients with recurrent glioblastoma and brain metastases, supporting continued clinical development. #NeOncTechnologies #NEO212 #BrainCancerResearch #Glioblastoma #ClinicalTrials #BiotechNews #DrugDevelopment #OncologyResearch #CNSCancer #HealthcareInnovation #JaneKing #NewsOut